AGN-242428

DRUG2 trials

Sponsors

Vitae Pharmaceuticals, Inc., AbbVie

Conditions

Dry Eye DiseaseDry Eye SyndromePlaque Psoriasis

Phase 1

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

CompletedNCT04030962

AbbVieDry Eye Disease, Dry Eye Syndrome

Start: 2020-03-04End: 2022-03-18Updated: 2025-05-20

Phase 2

AGN-242428 in the Treatment of Plaque Psoriasis

TerminatedNCT03339999

Vitae Pharmaceuticals, Inc.Plaque Psoriasis

Start: 2017-11-15End: 2018-04-20Updated: 2021-04-06

Related Papers

Selecting Vehicle Comparators in Dry Eye Disease Clinical Trials: Implications for Efficacy and Safety Assessment and Regulatory Outcomes.

2026-09-07